Oncology Today with Dr Neil Love: Adjuvant Therapy for ER-Positive Breast Cancer (Audio Program) is organized by Research To Practice (RTP).

Release Date: November 01, 2020
Expiration Date: November 30, 2021

Accreditation:
Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Learning Objectives:
• Evaluate emerging Phase III data documenting the benefit of abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative early breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
• Recall the design and eligibility criteria of ongoing clinical trials evaluating the role of adjuvant CDK4/6 inhibitors for localized ER-positive breast cancer, and enroll or refer appropriate patients for participation.
• Appreciate the unique side effects associated with CDK4/6 inhibitors, and develop preventive and emergent strategies to reduce or ameliorate these toxicities.
• Individualize the selection and duration of adjuvant systemic therapy for newly diagnosed ER-positive breast cancer, considering the patient’s clinical presentation (eg, age, stage, tumor size, nodal involvement, menopausal status, comorbidities) and disease- and treatment-related factors.

• CME : 1
• MOC : 1

This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

Number of Health Care Professionals Registered: 0 Number